Aging and inflammation go hand in hand, so developing a drug to block the inflammation-causing multiprotein complex NLRP3 was ...
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...
Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 ...
Inflazome has raised €40 million ($46 million). The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases. Irish-British biotech Inflazome ...
Northwestern Medicine investigators recently discovered that the mitochondrial respiratory chain — a series of protein complexes essential for a cellular respiration and energy production — is ...
BUFFALO, NY-August 8, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, “Inhibiting ...
Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and ...
Novo Nordisk announced Thursday that it has entered an exclusive development and license agreement for $70 million with Ventus Therapeutics for its NLRP3 inhibitor program. As part of the transaction, ...
SARS-CoV-2, which belongs to the family Coronaviridae, is a highly infectious virus that mainly infects the respiratory tract of humans. The viral genome of SARS-CoV-2 is found within the nucleocapsid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results